MarketBeat55d agoneutral
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts AheadNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3125last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Motley Fool55d agobullish
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?MarketBeat57d agoneutral
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic FibrosisMotley Fool58d agobullish
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in SeptemberStockStory59d agoneutral
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics StocksMotley Fool65d agobullish
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?Motley Fool67d agobullish
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026Barchart67d agoneutral
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?Simply Wall St.68d agoneutral
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader ChecksSimply Wall St.68d agoneutral
Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth HoldsInvestorsHub68d agoneutral
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth PlatformMotley Fool76d agoneutral
Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide